FO
TEVA icon

FT Options’s Teva Pharmaceuticals TEVA Stock Holding History

FT Options’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		$9K Buy
+20,000
New +$450K 0.01% 190

Other funds holding TEVA

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
HCM
Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return
NC
Northern Cross Boston, Massachusetts $279M AUM 1.98% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

FT Options's TEVA Position: Q3 2017 in Review

FT Options opened a new position in Teva Pharmaceuticals (TEVA) in Q3 2017: 130,723 shares worth $2.3M. The stake represents 3.47% of the portfolio and ranks #3 among its holdings. This is a return to the name: FT Options previously reported a position in TEVA as recently as Q4 2016.

FT Options first reported a position in TEVA in Q3 2016 and has held it in 3 quarters since. 535 funds tracked by Wall St. Rank hold TEVA as of Q3 2017.

  • FT Options held 130,723 shares of Teva Pharmaceuticals worth $2.3M as of Q3 2017.
  • Teva Pharmaceuticals was a new FT Options position in Q3 2017.
  • Teva Pharmaceuticals made up 3.47% of FT Options's portfolio in Q3 2017, its #3 holding.
  • FT Options first reported a position in Teva Pharmaceuticals in Q3 2016 and has held it in 3 quarters since.
  • 535 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q3 2017.

Based on FT Options's 13F filing for Q3 2017, filed 13 Nov 2017.